Lexaria Bioscience Corp. announces that the U.S. Food and Drug Administration (?FDA?) has confirmed effectiveness as of February 28, 2024 of the Company?s investigational new drug (?IND?) application thereby cleared for Lexaria to conduct its planned U.S. Phase 1b hypertension clinical trial HYPER-H23-1 utilizing DehydraTECHCBD. Lexaria is pleased to have complied with the FDA?s rules and procedures for clearance to perform this important registrational trial.

The Company will further announce when it is ready to begin the study, subject to certain conditions including raising sufficient funding. Background and Medical/Market Rationale From 2018 through 2022, Lexaria has previously conducted five human clinical studies of DehydraTECH-CBD in an aggregate total of 134 healthy normal and hypertensive volunteers, without recording a single serious adverse event (the ?Studies?). The Studies evidenced significant reductions in resting blood pressure over both acute and multi-week dosing regimens, and also produced zero serious adverse events; suggesting that DehydraTECH-CBD has the potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics.